Stockscreener 앱 받기
3.95
10.43%
-0.46
시간 외 거래:
4.92
0.97
+24.56%
전일 마감가:
$4.41
열려 있는:
$4.27
하루 거래량:
278.72K
Relative Volume:
1.92
시가총액:
$86.45M
수익:
순이익/손실:
$-69.87M
주가수익비율:
-1.231
EPS:
-3.2089
순현금흐름:
$-61.75M
1주 성능:
+2.33%
1개월 성능:
-31.30%
6개월 성능:
-28.57%
1년 성능:
-63.99%
1일 변동 폭
$3.89
$4.31
1주일 범위
$3.64
$4.54
52주 변동 폭
$3.35
$16.60
Aardvark Therapeutics Inc Stock (AARD) Company Profile
명칭
Aardvark Therapeutics Inc
전화
(858) 225-7696
주소
4370 LA JOLLA VILLAGE DRIVE, SAN DIEGO
Compare AARD vs VRTX, REGN, MRNA, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AARD
Aardvark Therapeutics Inc
|
3.95 | 86.45M | 0 | -69.87M | -61.75M | -3.2089 |
VRTX
Vertex Pharmaceuticals Inc
|
535.17 | 135.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
819.09 | 84.33B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
202.63 | 80.90B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
875.76 | 55.07B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
382.27 | 43.24B | 5.76B | 514.49M | 1.10B | 4.4813 |
Aardvark Therapeutics Inc Stock (AARD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-05-15 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2026-03-02 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2026-03-02 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2026-03-02 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-03-02 | 다운그레이드 | Stifel | Buy → Hold |
| 2026-01-28 | 개시 | B. Riley Securities | Buy |
| 2025-12-23 | 개시 | Oppenheimer | Outperform |
| 2025-12-12 | 개시 | William Blair | Outperform |
| 2025-12-03 | 개시 | Raymond James | Strong Buy |
| 2025-11-07 | 개시 | BTIG Research | Buy |
| 2025-09-29 | 개시 | Stifel | Buy |
| 2025-06-30 | 개시 | H.C. Wainwright | Buy |
| 2025-03-10 | 개시 | BofA Securities | Buy |
| 2025-03-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-03-10 | 개시 | Morgan Stanley | Overweight |
| 2025-03-10 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Aardvark Therapeutics Inc 주식(AARD)의 최신 뉴스
All You Need to Know About Aardvark Therapeutics, Inc. (AARD) Rating Upgrade to Buy - Zacks Investment Research
Attention Long-Term Shareholders of Aardvark Therapeutics, - GlobeNewswire
Aardvark Therapeutics, Inc. (NASDAQ: AARD) Investor Alert: Deadline in Lawsuit on October 13, 2026 - openPR.com
AARD FINAL DEADLINE ALERT: Aardvark Therapeutics Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit - PR Newswire
AARD DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important October 13 Deadline in Securities Class Action – AARD - Macau Business
AARD DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important October 13 Deadline in Securities Class Action – AARD - GlobeNewswire Inc.
AARD 截止日期通知：知名律師事務所 ROSEN 提醒 Aardvark Therapeutics, Inc. 投資人，應於證券集體訴訟重要期限 10 月 13 日之前委任法律律師 – AARD - GlobeNewswire Inc.
AARD DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, - GlobeNewswire
URGENT AARDVARK DEADLINE: Bragar Eagel & Squire, P.C. Urges Aardvark Therapeutics, Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 13th - GlobeNewswire Inc.
URGENT AARDVARK DEADLINE: Bragar Eagel & Squire, P.C. Urges Aardvark Therapeutics, Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 13th - The Daily Tribune News
URGENT AARDVARK DEADLINE: Bragar Eagel & Squire, P.C. Urges - GlobeNewswire
Lost Money on Aardvark Therapeutics, Inc. (AARD)? Contact Levi & Korsinsky to Join Class Action Before October 13, 2026 - ACCESS Newswire
AARD 4-DAY DEADLINE ALERT: Aardvark Therapeutics Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before October 13, 2026 Lead Plaintiff DeadlineHBSS - GlobeNewswire Inc.
AARD DEADLINE ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important October 13 Deadline in Securities Class Action – AARD - GlobeNewswire Inc.
Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Erasca, Inc. (NASDAQ: ERAS); and New Era Energy & Digital, Inc. (NASDAQ: NUAI): Grabar Law Office is Investigating Claims on Your Behalf - GlobeNewswire Inc.
Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors - GlobeNewswire Inc.
AARD Deadline: Rosen Law Firm Urges Aardvark Therapeutics, Inc. (NASDAQ: AARD) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights - Business Wire
Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors – AARD - FinancialContent
Bronstein, Gewirtz & Grossman LLC Urges Aardvark Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.
AARDVARK THERAPEUTICS (NASDAQ: AARD) SECURITIES CLASS - GlobeNewswire
AARDVARK THERAPEUTICS (NASDAQ: AARD) SECURITIES CLASS ACTION: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Investors to Secure Counsel Before Important October 13 Deadline - GlobeNewswire Inc.
Bragar Eagel & Squire, P.C. Urges Aardvark Therapeutics, Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 13th - The Daily Tribune News
Did You Lose Money on Aardvark Therapeutics, Inc. (AARD)? Levi & Korsinsky Urges Investors to Act Before October 13, 2026 - ACCESS Newswire
Did You Lose Money on Aardvark Therapeutics, Inc. (AARD)? Levi & Korsinsky Urges Investors to Act Before October 13, 2026 - ACCESS Newswire
AARD Deadline: AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit - the-dispatch.com
Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Los - The National Law Review
Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
AARDVARK DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important October 13 Deadline in Securities Class Action – AARD - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman LLC Urges Aardvark Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.
AARD Stock News: Robbins LLP Reminds Aardvark Therapeutics, Inc. Stockholders to Contact the Firm Before the October 13, 2026 Lead Plaintiff Deadline - PR Newswire
AARD Stock News: Robbins LLP Reminds Aardvark Therapeutics, Inc. Stockholders to Contact the Firm Before the October 13, 2026 Lead Plaintiff Deadline - Morningstar
Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors – AARD - FinancialContent
Aardvark Therapeutics, Inc. (AARD) LawsuitInvestors Urged to Contact Levi & Korsinsky Before October 13, 2026 - ACCESS Newswire
Aardvark Therapeutics (AARD) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before October 13, 2026 Lead Plaintiff Deadline - TMX Newsfile
AARDVARK DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AARD - GlobeNewswire Inc.
AARDVARK DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, - GlobeNewswire
AARD FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Aardvark Therapeutics, Inc. ... - pmg-ky3.com
Bronstein, Gewirtz & Grossman LLC Urges Aardvark Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.
Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and DirectorsAARD - PR Newswire
AARD Lead Plaintiff Deadline is Quickly Approaching - GlobeNewswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
מועד אחרון לתביעה ייצוגית נגד AARDVARK: רוזן, יועץ למשקיעים מיומן, קורא למשקיעי Aardvark Therapeutics, Inc. לשכור ייצוג משפטי לקראת מועד חשוב בתביעה ייצוגית בניירות הערך – AARD - GlobeNewswire Inc.
Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuit Before October 13 Deadline - TMX Newsfile
AARDVARK THERAPEUTICS, INC. (AARD) SHAREHOLDER ALERT - GlobeNewswire
AARDVARK THERAPEUTICS, INC. (AARD) SHAREHOLDER ALERT - GlobeNewswire
Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts - Stocktwits
AARD Deadline: AARD Investors with Losses in Excess of $100K Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit - AOL.ca
Deadline Alert: Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit - GlobeNewswire Inc.
Lost Money on Aardvark Therapeutics, Inc. (AARD)? Urged to Join Class Action Before October 13, 2026Contact Levi & Korsinsky - ACCESS Newswire
Aardvark Therapeutics Inc (AARD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Aardvark Therapeutics Inc 주식 (AARD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| NELSON SUN | Officer |
Sep 11 '26 |
Proposed Sale |
5.01 |
33,911 |
169,894 |
0 |
| Sun Nelson | See Remarks |
Sep 10 '26 |
Sale |
5.00 |
14,754 |
73,779 |
97,475 |
| NELSON SUN | Officer |
Sep 10 '26 |
Proposed Sale |
4.92 |
42,843 |
210,788 |
0 |
| Sun Nelson | Chief Financial Officer |
Dec 11 '25 |
Buy |
14.40 |
3,000 |
43,200 |
108,484 |
| Lee Tien-Li | Chief Executive Officer |
Dec 11 '25 |
Buy |
14.48 |
7,000 |
101,395 |
1,551,613 |
| Lee Tien-Li | Chief Executive Officer |
Oct 15 '25 |
Option Exercise |
4.24 |
1,229 |
5,211 |
1,544,613 |
| Jones Bryan | Chief Operating Officer |
Oct 15 '25 |
Option Exercise |
4.24 |
1,250 |
5,300 |
1,250 |
0.68%
3.98%
자본화:
|
볼륨(24시간):